NCT04423744 is a Phase 1 clinical trial of BAY1817080 in Cough, sponsored by Bayer.

Who is sponsoring NCT04423744?

NCT04423744 is sponsored by Bayer.

What drugs are being tested in NCT04423744?

Interventions in NCT04423744: BAY1817080, Moxifloxacin, Placebo.

What condition does NCT04423744 study?

NCT04423744 studies Cough, Endometriosis, Overactive Bladder.

Is NCT04423744 still recruiting?

NCT04423744 is currently completed. Last updated 24 January 2022.

Last reviewed 2022-01-24 · How we verify

NCT04423744

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants

Completed Phase 1 Last updated 24 January 2022

What this trial tests

Phase 1 trial testing BAY1817080 in Cough in 42 participants. Completed in 21 January 2021.

Timeline

18 June 2020

Primary endpoint
9 November 2020

21 January 2021

Quick facts

Lead sponsor	Bayer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	other
Enrollment	42
Start date	18 June 2020
Primary completion	9 November 2020
Estimated completion	21 January 2021
Sites	1 location across Germany

Drugs / interventions tested

BAY1817080 — full drug profile →
Moxifloxacin (moxifloxacin) — full drug profile →
Placebo

Conditions studied

Cough — all drugs for Cough →
Endometriosis — all drugs for Endometriosis →
Overactive Bladder — all drugs for Overactive Bladder →

Sponsor

Bayer — full company profile →

Who can join

Adults 18 to 65, any sex, with Cough or Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, researchers want to find whether the study drug BAY1817080 has an effect on the electrocardiogram (ECG). 40 healthy male or female participants with the age of 18 to 65 years will be enrolled into this study. The ECG of the participants will be monitored closely by the researchers to detect any change after intake of the study medication.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment.
Chen LH, Lo WC, Huang HY, Wu HM. · · 2023 · cited 43× · PMID 37108664 · DOI 10.3390/ijms24087503
Safety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: A systematic review and meta-analysis of randomized controlled trials.
Abu-Zaid A, Aljaili AK, Althaqib A, Adem F, et al · · 2021 · cited 12× · PMID 34012479 · DOI 10.4103/atm.atm_417_20

Verify or expand the search:

Other trials of BAY1817080

Trials testing the same drug.

NCT04802343 — A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men · Phase 1 · completed
NCT04614246 — Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Compari · Phase 2 · terminated
NCT04641273 — A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants Wit · Phase 2 · terminated
NCT04562155 — Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patient · Phase 2 · completed
NCT04545580 — Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB) · Phase 2 · completed

Other recruiting trials for Cough

Currently open trials in the same condition.

NCT07171099 — Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children · Phase 3 · recruiting
NCT06999577 — The Mechanism Versus PPI Trial · Phase 4 · recruiting
NCT06979141 — Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia · Phase 3 · recruiting
NCT06918756 — Development of a Cough Control Questionnaire (CCQ) · recruiting
NCT06878209 — Cough and Hemorrhoids · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04423744 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 24 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04423744.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing